You're viewing a free preview.You're viewing a free preview — a sample of each dataset.

Regulatory

FDA, EMA and policy developments that move aging research and the longevity market.

155 regulatory items tracked

Item	Category	Significance	Date
FDA clears Surrozen's IND for SZN-8141, a Wnt-agonist and VEGF-blocking antibody for diabetic macular edema	FDA	Medium	10/02/26
FDA leaders say aging and longevity are a priority at ARDD, with aging to feature in the next Focus Areas of Regulatory Science	FDA	High	10/02/26
FDA approves AbbVie's JUVMO (tavapadon) for Parkinson's disease	FDA	High	09/28/26
FDA clears C2N Diagnostics' PrecivityAD2, first Alzheimer's blood test for adults as young as 40	Approval	High	08/20/26
Enveda reports positive Phase 1 results for ENV-308, first pill designed from the chemistry of exercise	Other	High	08/18/26
FDA grants accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) plus nivolumab for advanced melanoma	FDA Approval	Medium	08/06/26
FDA approves mFLUSIVA (mRNA-1010), Moderna’s mRNA influenza vaccine for adults 50 and older	FDA Approval	High	08/06/26
FDA Approves Lipfendra (enlicitide) as First Oral PCSK9 Therapy for LDL Cholesterol Reduction	FDA Approval	Medium	07/16/26
FDA Grants RMAT Designation to Allocetra for Age-related Knee Osteoarthritis	RMAT Designation	High	07/13/26
Enlivex receives FDA RMAT designation for Allocetra in age-related knee osteoarthritis	Designation	High	07/13/26

Showing 10 of 155 regulatory items

Peek at other modules

Daily longevity science headlines — aging research, deals, trials, and policy — with AI summaries.

The longevity science company universe by segment, stage, geography and capital raised.

Every disclosed longevity science round — size, stage and the investors behind it.

Longevity science and aging research trials by phase, sponsor, status and indication.

Who is joining, leaving and founding across longevity science and aging research.

Peer-reviewed aging research distilled into investor-relevant takeaways.